Archive for the 'Epithelioid' Category
Epitheliod mesothelioma makes up between 50% and 70% of all diagnosed cases of mesothelioma; it also tends to have the best prognosis.
November 3rd, 2007. Novel expression of kallikreins, kallikrein-related peptidases and kinin receptors in human pleural mesothelioma
KRP/hK2, 6, 8 and 9 were also expressed in the cytoplasm and nuclei of mesothelioma cells, whereas KRP/hK5 and hK7 showed predominantly cytoplasmic localisation. This is a first report, but further studies are required to determine whether these proteins have a functional role in the pathogenesis of mesothelioma and/or may be potential biomarkers for pleural mesothelioma.
Posted in Biphasic or Mixed, Diagnosis & Differentiation, Epithelioid, Full Archive, New & Novel, Pleural, Sarcomatoid, Serum Marker/Blood Test, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
October 3rd, 2007. Apparent spontaneous complete regression of a multifocal malignant mesothelioma of the pleura
This case demonstrates that this tumour may, very rarely, regress spontaneously, with no recurrence for many years. A greater knowledge of the underlying immune mechanisms would aid future management of this and other tumours.
September 22nd, 2007. Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma
Conclusions: Pleural biopsy performed using thoracoscopy is considered to be the cornerstone of the diagnosis and pleural staging of MPM. However, this procedure appears to be less efficient in diagnosing the histologic subtype as either epithelial or biphasic.
August 2nd, 2007. h-Caldesmon, Calretinin, Estrogen Receptor, and Ber-EP4: A Useful Combination of Immunohistochemical Markers for Differentiating Epithelioid Peritoneal Mesothelioma From Serous Papillary Carcinoma of the Ovary
3%). The relationship between the values of sensitivity and specificity of each marker using receiver operating characteristic analysis permitted the identification of h-CD, calretinin, ER, and Ber-EP4 as the markers with the best performance in differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
June 19th, 2007. Establishment and characterization of two distinct malignant mesothelioma cell lines with common clonal origin
Remarkably, one xenograft from MM-Z03E revealed overexpression of p53 and widely invasive growth. In conclusion, both cell lines are useful in vivo and in vitro model systems to study the underlying genetic mechanisms of biphasic differentiation in MM, which can be of certain value considering the increasing relevance of assessing MM tumor biology for the clinical management of this disease.
June 15th, 2007. Primary omental Gastrointestinal stromal tumor (GIST)
Conclusion: Our case demonstrated a weak immunohistochemical expression of c-kit (CD117) and a point mutation in PDGFRA exon 12 resulting in an Asp for Val561 substitution. Imatinib therapy as an adjuvant to complete resection has been carried out safely. Because of the rarity of primary omental GISTs, it is inevitable to analyze accumulating data from case reports for a better and more detailed understanding of primary omental GISTs.
June 2nd, 2007. A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation
Conclusion: In diagnosing mesothelioma it is necessary to use a panel of immunohistochemical stains, which should contain antibodies to markers for adenocarcinoma and mesothelioma. Due to the high costs of such a study, a two-stage method is
May 15th, 2007. Diagnostic utility of D2-40 and podoplanin in effusion cell blocks
It is concluded that D2-40 and podoplanin are very useful markers for mesotheliomas. Since these markers are extremely helpful in differentiating epithelioid mesothelioma from metastatic adenocarcinoma, they shall be a valuable addition to the battery of markers used to differentiate the two entities.
April 27th, 2007. Spontaneous Peritoneal Malignant Mesothelioma in a Geriatric Japanese Macaque (Macaca fuscata)
Neoplastic cells were strongly positive to cytokeratin, and occasionally to vimentin. Based on gross and histopathological findings, this tumor was diagnosed as an epithelial type of peritoneal malignant mesothelioma, the first reported case in the non-human primates.
April 27th, 2007. Lymphohistiocytoid Variant of Malignant Mesothelioma of the Pleura: A Series of 22 Cases
We suggest that it should be reclassified as an epithelioid variant because of its similar behavioural characteristics. There was no evidence of Epstein-Barr virus-related infection.
April 7th, 2007. Diagnostic procedures of pleural malignant mesothelioma: our experience
Conclusion: The accurate diagnosis of MM is mandatory for appropriate treatment decision (surgical or nonsurgical). Our results demonstrate that HMBE-1 is a most useful diagnostic antibody for epithelioid MM, and TTF-1 for lung adenocarcinoma (its thyroid origin excluded) involving pleura.
March 30th, 2007. Value of antimesothelioma HBME-1 in the diagnosis of inflammatory and malignant pleural effusions
33%) cases; the staining pattern in metastatic adenocarcinoma cells was thin membrane and focal cytoplasmic. HBME-1 has a moderate sensibility and specificity for mesothelial cells and can be used as part of a panel for differentiation of malignant and reactive mesothelial cells from adenocarcinoma in pleural effusions.
March 21st, 2007. Immunohistochemical expression of osteopontin in epithelioid mesotheliomas and reactive mesothelial proliferations
Osteopontin expression is not restricted to malignant mesothelial proliferations, and immunohistochemical analysis for osteopontin is not helpful in determining reactive vs malignant mesothelial proliferations. The reported usefulness of osteopontin as a serum tumor marker for mesothelioma may be due to differences in the amount or character of secreted protein in malignant mesothelioma compared with reactive mesothelial proliferations.
March 16th, 2007. D2-40 and calretinin – a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation
66. These data indicate that a combination of calretinin and D2-40 will improve diagnostic accuracy for spindle cell lesions of the pleura, whereas almost all epithelioid mesotheliomas are identified by calretinin alone.
February 24th, 2007. Quantification of alternative mRNA species and identification of thioredoxin reductase 1 isoforms in human tumor cells
5, previously not identified in human cells, were detected by mass spectrometry. Our data show differential expression of TrxR1 mRNA forms in malignant mesothelioma of different phenotype, and investigation of alternative transcript variants of TrxR1 could be a valuable tool in the diagnostics and characterization of tumors.
February 24th, 2007. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma
2, and EMA; 41% for CK 5/6; 47% for vimentin; 20% for thrombomodulin; 69% for mesothelin; 98% for CEA; 73% for CA19-9; and 80% for CA125. For distinguishing between epithelioid mesothelioma and lung adenocarcinoma, the combination of CEA, calretinin and each WT1 or thrombomodulin was suggested to be the best panel of immunohistochemical markers.
February 7th, 2007.
Conclusions: These data strongly suggest the significant usefulness of D2-40 and calretinin as positive markers, and of CEA and TTF-1 as negative markers, for pleural mesothelioma. The 4-antibody immunohistochemical panel showed high sensitivity and specificity with regard to differentiation of epithelioid mesothelioma from lung adenocarcinoma.
February 3rd, 2007. Malignant mesothelioma of the tunica vaginalis testis
The aggressiveness and poor prognosis of this tumor require radical surgery as the primary therapy. We describe the case of a 45 year old patient, in whom an epithelioid mesothelioma was incidentally detected after hydrocelectomy.
January 26th, 2007. Survey of surgical treatment of malignant pleural mesothelioma in Japan
086) with a marginal significance, indicating that complete surgical resection of the tumor and perioperative adjuvant therapy could be effective treatment for MPM in Japan. Thus, the development of multimodality therapy including surgical treatment for this disease may be required to improve surgical results of MPM patients.
Posted in Biphasic or Mixed, Chemotherapy, Determining Efficacy, Epithelioid, Extrapleural Pneumonectomy (EPP), Full Archive, General, Pleural, Pleurectomy/decortication, Sarcomatoid, Surgery, Survival, Treatment, Trimodality Therapy, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
January 26th, 2007. Diffuse malignant pleural mesothelioma
Median survival time after diagnosis was 3 (range, 0 to 51) months. Of the 11 patients, 7 (64%) died within 6 months after the first presentation, and only 1 (9%) lived longer than 2 years after diagnosis.
Posted in Biphasic or Mixed, Chemotherapy, Epithelioid, Extrapleural Pneumonectomy (EPP), Full Archive, Intrapleural Chemotherapy, Pleural, Sarcomatoid, Surgery, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
|
|  |
